Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Liver International

Volumn 36, Issue 12, 2016, Pages 1755-1764

  Su, Tung Hung ^a,b   Hu, Tsung Hui ^c   Chen, Chi Yi ^d   Huang, Yi Hsiang ^e,f   Chuang, Wan Long ^g   Lin, Chun Che ^h   Wang, Chia Chi ⁱ   Su, Wei Wen ^j   Chen, Ming Yao ^k   Peng, Cheng Yuan ^l   Chien, Rong Nan ^m   Huang, Yi Wen ⁿ   Wang, Horng Yuan ^o   Lin, Chih Lin ^p   Yang, Sheng Shun ^q   Chen, Tsung Ming ^r   Mo, Lein Ray ^s   Hsu, Shih Jer ^a   Tseng, Kuo Chih ^t   Hsieh, Tsai Yuan ^u   Suk, Fat Moon ^v   Hu, Chi Tan ^t   Bair, Ming Jong ^o   Liang, Cheng Chao ^w   Lei, Yung Chao ^a   Tseng, Tai Chung ^a   Chen, Chi Ling ^b   Kao, Jia Horng ^a,b   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ TAIPEI TZU CHI HOSPITAL   (Taiwan)

^j CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^k TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^l CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^m CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

ⁿ CATHAY GENERAL HOSPITAL   (Taiwan)

^o MACKAY MEMORIAL HOSPITAL   (Taiwan)

^p TAIPEI CITY HOSPITAL   (Taiwan)

^q TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^r TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^s TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^t BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^u TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^v TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^w FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

antiviral therapy; liver cancer; nucleos(t)ide analogue; spontaneous bacterial peritonitis; variceal bleeding

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER RISK; CHILD PUGH SCORE; CHRONIC HEPATITIS B; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; RISK REDUCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VARICEAL BLEEDING; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TAIWAN; TREATMENT OUTCOME;

ADULT; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 84994810216     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13253     Document Type: Article

References (32)

1. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2015;63:844–855.
2. Su TH, Kao JH. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol. 2015;9:141–154.
3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.
4. Liaw YF. Impact of therapy on the long-term outcome of chronic hepatitis B. Clin Liver Dis. 2013;17:413–423.
5. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.
6. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547.
7. Wu CY, Lin JT, Ho HJ, et al. Association of Nucleos(t)ide analogue therapy with reduced risk of Hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology. 2014;147:143–151.e145.
8. Gordon SC, Lamerato LE, Rupp LB, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol. 2014;12:885–893.
9. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Intl. 2012;6:531–561.
10. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399–408.
11. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109:1223–1233.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
13. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802–1829.
14. Bergstralh EJ, Kosanke JL. Computerized matching of cases to controls. Mayo Fund Tech Rep. 1995;56:1–29.
15. Coffin CS, Rezaeeaval M, Pang JX, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40:1262–1269.
16. Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631–3638.
17. Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289–1295.
18. Ahn J, Lim JK, Lee HM, et al. Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE Study. Am J Gastroenterol. 2016;111:1297–1304.
19. Yasunaka T, Ikeda F, Wada N, et al. Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients. Acta Med Okayama. 2016;70:1–12.
20. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–352.
21. Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63:1943–1950.
22. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62:363–370.
23. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109–1116.
24. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800–806.
25. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174.
26. Montuclard C, Hamza S, Rollot F, et al. Causes of death in people with chronic HBV infection: a population-based cohort study. J Hepatol. 2015;62:1265–1271.
27. Hsu YC, Wu CY, Lane HY, et al. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B. J Antimicrob Chemother. 2014;69:1920–1927.
28. Yang SC, Lee CM, Hu TH, et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013;68:2154–2163.
29. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760–765.
30. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–356.
31. Lin CL, Kao JH. Perspectives and control of hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2015;114:901–909.
32. Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436.